@misc{condadoBrainAgeModeratesAssociations2025,
	title = {{BrainAge} moderates associations between {Alzheimer}’s disease biomarkers and cognitive decline: a meta-analysis across {A4}/{LEARN}, {HABS} and {ADNI} cohorts},
	copyright = {© 2025, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NoDerivs 4.0 International), CC BY-ND 4.0, as described at http://creativecommons.org/licenses/by-nd/4.0/},
	shorttitle = {{BrainAge} moderates associations between {Alzheimer}’s disease biomarkers and cognitive decline},
	url = {https://www.medrxiv.org/content/10.1101/2025.07.07.25331026v1},
	doi = {10.1101/2025.07.07.25331026},
	abstract = {BrainAge delta, the difference between a person’s predicted brain age and their chronological age, is a promising marker of the accumulation of neurodegeneration that may increase vulnerability to Alzheimer’s disease (AD). We examined whether BrainAge delta moderates the relationship between AD biomarkers and longitudinal cognitive decline performing a meta-analysis across three cohorts (2,279 cognitively unimpaired [CU]; 416 with mild cognitive impairment [MCI]). Higher BrainAge delta was linked to faster decline in CU (β = -0.13 [-0.21, -0.06], p = 0.018, I2=1\%, τ2=0.00) and more strongly in MCI (β = -0.31 [-0.30, -0.24], p {\textless} 1x10-16). BrainAge also interacted with Aβ-PET (β = -0.09 [-0.15, -0.05], p = 0.0054, I2=12\%, τ2 = 0.00) and plasma pTau217 (β = -0.09 [-0.15, -0.03], p = 0.018, I2=8\%, τ2 = 0.00), but not Tau-PET, to impact cognitive decline. We next tested its utility for clinical trial enrichment. Sequential screening with pTau217 and BrainAge delta reduced required sample size for prevention trials by 76\%, versus 59\% using pTau217 alone. These findings support BrainAge delta as a marker of neurodegeneration and may serve as an enrichment tool for AD prevention trials.},
	language = {en},
	urldate = {2025-10-15},
	publisher = {medRxiv},
	author = {Condado, Jorge Garcia and Klinger, Hannah M. and Birkenbihl, Colin and Cuppels, Madison and Liu, Annie and Elorriaga, Iñigo Tellaetxe and Seto, Mabel and Couglan, Gillian T. and Properzi, Michael J. and Rentz, Dorene M. and Schultz, Aaron P. and Erramuzpe, Asier and Yang, Hyun-Sik and Chhatwal, Jasmeer and Johnson, Keith A. and Healy, Brian C. and Cortes, Jesus M. and Sperling, Reisa A. and Donohue, Michael and Hohman, Timothy J. and Diez, Ibai and Buckley, Rachel F. and Initiative, the Alzheimer’s Disease Neuroimaging},
	month = jul,
	year = {2025},
	note = {ISSN: 3067-2007
Pages: 2025.07.07.25331026},
}

{"_id":"Sce9h6NrRu2fY64Wj","bibbaseid":"condado-klinger-birkenbihl-cuppels-liu-elorriaga-seto-couglan-etal-brainagemoderatesassociationsbetweenalzheimersdiseasebiomarkersandcognitivedeclineametaanalysisacrossa4learnhabsandadnicohorts-2025","author_short":["Condado, J. G.","Klinger, H. M.","Birkenbihl, C.","Cuppels, M.","Liu, A.","Elorriaga, I. T.","Seto, M.","Couglan, G. T.","Properzi, M. J.","Rentz, D. M.","Schultz, A. P.","Erramuzpe, A.","Yang, H.","Chhatwal, J.","Johnson, K. A.","Healy, B. C.","Cortes, J. M.","Sperling, R. A.","Donohue, M.","Hohman, T. J.","Diez, I.","Buckley, R. F.","Initiative, t. A. D. N."],"bibdata":{"bibtype":"misc","type":"misc","title":"BrainAge moderates associations between Alzheimer’s disease biomarkers and cognitive decline: a meta-analysis across A4/LEARN, HABS and ADNI cohorts","copyright":"© 2025, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NoDerivs 4.0 International), CC BY-ND 4.0, as described at http://creativecommons.org/licenses/by-nd/4.0/","shorttitle":"BrainAge moderates associations between Alzheimer’s disease biomarkers and cognitive decline","url":"https://www.medrxiv.org/content/10.1101/2025.07.07.25331026v1","doi":"10.1101/2025.07.07.25331026","abstract":"BrainAge delta, the difference between a person’s predicted brain age and their chronological age, is a promising marker of the accumulation of neurodegeneration that may increase vulnerability to Alzheimer’s disease (AD). We examined whether BrainAge delta moderates the relationship between AD biomarkers and longitudinal cognitive decline performing a meta-analysis across three cohorts (2,279 cognitively unimpaired [CU]; 416 with mild cognitive impairment [MCI]). Higher BrainAge delta was linked to faster decline in CU (β = -0.13 [-0.21, -0.06], p = 0.018, I2=1%, τ2=0.00) and more strongly in MCI (β = -0.31 [-0.30, -0.24], p \\textless 1x10-16). BrainAge also interacted with Aβ-PET (β = -0.09 [-0.15, -0.05], p = 0.0054, I2=12%, τ2 = 0.00) and plasma pTau217 (β = -0.09 [-0.15, -0.03], p = 0.018, I2=8%, τ2 = 0.00), but not Tau-PET, to impact cognitive decline. We next tested its utility for clinical trial enrichment. Sequential screening with pTau217 and BrainAge delta reduced required sample size for prevention trials by 76%, versus 59% using pTau217 alone. These findings support BrainAge delta as a marker of neurodegeneration and may serve as an enrichment tool for AD prevention trials.","language":"en","urldate":"2025-10-15","publisher":"medRxiv","author":[{"propositions":[],"lastnames":["Condado"],"firstnames":["Jorge","Garcia"],"suffixes":[]},{"propositions":[],"lastnames":["Klinger"],"firstnames":["Hannah","M."],"suffixes":[]},{"propositions":[],"lastnames":["Birkenbihl"],"firstnames":["Colin"],"suffixes":[]},{"propositions":[],"lastnames":["Cuppels"],"firstnames":["Madison"],"suffixes":[]},{"propositions":[],"lastnames":["Liu"],"firstnames":["Annie"],"suffixes":[]},{"propositions":[],"lastnames":["Elorriaga"],"firstnames":["Iñigo","Tellaetxe"],"suffixes":[]},{"propositions":[],"lastnames":["Seto"],"firstnames":["Mabel"],"suffixes":[]},{"propositions":[],"lastnames":["Couglan"],"firstnames":["Gillian","T."],"suffixes":[]},{"propositions":[],"lastnames":["Properzi"],"firstnames":["Michael","J."],"suffixes":[]},{"propositions":[],"lastnames":["Rentz"],"firstnames":["Dorene","M."],"suffixes":[]},{"propositions":[],"lastnames":["Schultz"],"firstnames":["Aaron","P."],"suffixes":[]},{"propositions":[],"lastnames":["Erramuzpe"],"firstnames":["Asier"],"suffixes":[]},{"propositions":[],"lastnames":["Yang"],"firstnames":["Hyun-Sik"],"suffixes":[]},{"propositions":[],"lastnames":["Chhatwal"],"firstnames":["Jasmeer"],"suffixes":[]},{"propositions":[],"lastnames":["Johnson"],"firstnames":["Keith","A."],"suffixes":[]},{"propositions":[],"lastnames":["Healy"],"firstnames":["Brian","C."],"suffixes":[]},{"propositions":[],"lastnames":["Cortes"],"firstnames":["Jesus","M."],"suffixes":[]},{"propositions":[],"lastnames":["Sperling"],"firstnames":["Reisa","A."],"suffixes":[]},{"propositions":[],"lastnames":["Donohue"],"firstnames":["Michael"],"suffixes":[]},{"propositions":[],"lastnames":["Hohman"],"firstnames":["Timothy","J."],"suffixes":[]},{"propositions":[],"lastnames":["Diez"],"firstnames":["Ibai"],"suffixes":[]},{"propositions":[],"lastnames":["Buckley"],"firstnames":["Rachel","F."],"suffixes":[]},{"propositions":[],"lastnames":["Initiative"],"firstnames":["the","Alzheimer’s","Disease","Neuroimaging"],"suffixes":[]}],"month":"July","year":"2025","note":"ISSN: 3067-2007 Pages: 2025.07.07.25331026","bibtex":"@misc{condadoBrainAgeModeratesAssociations2025,\n\ttitle = {{BrainAge} moderates associations between {Alzheimer}’s disease biomarkers and cognitive decline: a meta-analysis across {A4}/{LEARN}, {HABS} and {ADNI} cohorts},\n\tcopyright = {© 2025, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NoDerivs 4.0 International), CC BY-ND 4.0, as described at http://creativecommons.org/licenses/by-nd/4.0/},\n\tshorttitle = {{BrainAge} moderates associations between {Alzheimer}’s disease biomarkers and cognitive decline},\n\turl = {https://www.medrxiv.org/content/10.1101/2025.07.07.25331026v1},\n\tdoi = {10.1101/2025.07.07.25331026},\n\tabstract = {BrainAge delta, the difference between a person’s predicted brain age and their chronological age, is a promising marker of the accumulation of neurodegeneration that may increase vulnerability to Alzheimer’s disease (AD). We examined whether BrainAge delta moderates the relationship between AD biomarkers and longitudinal cognitive decline performing a meta-analysis across three cohorts (2,279 cognitively unimpaired [CU]; 416 with mild cognitive impairment [MCI]). Higher BrainAge delta was linked to faster decline in CU (β = -0.13 [-0.21, -0.06], p = 0.018, I2=1\\%, τ2=0.00) and more strongly in MCI (β = -0.31 [-0.30, -0.24], p {\\textless} 1x10-16). BrainAge also interacted with Aβ-PET (β = -0.09 [-0.15, -0.05], p = 0.0054, I2=12\\%, τ2 = 0.00) and plasma pTau217 (β = -0.09 [-0.15, -0.03], p = 0.018, I2=8\\%, τ2 = 0.00), but not Tau-PET, to impact cognitive decline. We next tested its utility for clinical trial enrichment. Sequential screening with pTau217 and BrainAge delta reduced required sample size for prevention trials by 76\\%, versus 59\\% using pTau217 alone. These findings support BrainAge delta as a marker of neurodegeneration and may serve as an enrichment tool for AD prevention trials.},\n\tlanguage = {en},\n\turldate = {2025-10-15},\n\tpublisher = {medRxiv},\n\tauthor = {Condado, Jorge Garcia and Klinger, Hannah M. and Birkenbihl, Colin and Cuppels, Madison and Liu, Annie and Elorriaga, Iñigo Tellaetxe and Seto, Mabel and Couglan, Gillian T. and Properzi, Michael J. and Rentz, Dorene M. and Schultz, Aaron P. and Erramuzpe, Asier and Yang, Hyun-Sik and Chhatwal, Jasmeer and Johnson, Keith A. and Healy, Brian C. and Cortes, Jesus M. and Sperling, Reisa A. and Donohue, Michael and Hohman, Timothy J. and Diez, Ibai and Buckley, Rachel F. and Initiative, the Alzheimer’s Disease Neuroimaging},\n\tmonth = jul,\n\tyear = {2025},\n\tnote = {ISSN: 3067-2007\nPages: 2025.07.07.25331026},\n}\n\n\n\n","author_short":["Condado, J. G.","Klinger, H. M.","Birkenbihl, C.","Cuppels, M.","Liu, A.","Elorriaga, I. T.","Seto, M.","Couglan, G. T.","Properzi, M. J.","Rentz, D. M.","Schultz, A. P.","Erramuzpe, A.","Yang, H.","Chhatwal, J.","Johnson, K. A.","Healy, B. C.","Cortes, J. M.","Sperling, R. A.","Donohue, M.","Hohman, T. J.","Diez, I.","Buckley, R. F.","Initiative, t. A. D. N."],"key":"condadoBrainAgeModeratesAssociations2025","id":"condadoBrainAgeModeratesAssociations2025","bibbaseid":"condado-klinger-birkenbihl-cuppels-liu-elorriaga-seto-couglan-etal-brainagemoderatesassociationsbetweenalzheimersdiseasebiomarkersandcognitivedeclineametaanalysisacrossa4learnhabsandadnicohorts-2025","role":"author","urls":{"Paper":"https://www.medrxiv.org/content/10.1101/2025.07.07.25331026v1"},"metadata":{"authorlinks":{}}},"bibtype":"misc","biburl":"https://bibbase.org/zotero-group/ifigaga/5481914","dataSources":["W7brgmpKWMqJ3okQ2"],"keywords":[],"search_terms":["brainage","moderates","associations","between","alzheimer","disease","biomarkers","cognitive","decline","meta","analysis","learn","habs","adni","cohorts","condado","klinger","birkenbihl","cuppels","liu","elorriaga","seto","couglan","properzi","rentz","schultz","erramuzpe","yang","chhatwal","johnson","healy","cortes","sperling","donohue","hohman","diez","buckley","initiative"],"title":"BrainAge moderates associations between Alzheimer’s disease biomarkers and cognitive decline: a meta-analysis across A4/LEARN, HABS and ADNI cohorts","year":2025}